

## Novel Coronavirus (2019-nCoV)

In December of 2019, an outbreak caused by a novel coronavirus (2019-nCoV) began in Wuhan City, Hubei Province, China. The full genome of this newly discovered coronavirus was released by the Chinese Center for Disease Control and Prevention, the Chinese Academy of Science and the Chinese Academy of Medical Science through the GISAID Initiative (<https://www.gisaid.org/>).

Through bioinformatic analysis of the released genomes (as of February 14, 2020), Applied BioCode does not predict cross-reactivity with the 2019-nCoV (now named as COVID-19) with any BioCode® Coronavirus assay. This includes the Coronavirus 229E, HKU1, NL63 and OC43 assays (collectively reported as Coronavirus) on the BioCode® Respiratory Pathogen Panel (RPP).

Please refer to the CDC and WHO for guidelines on testing specimens from patients under investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV).

<https://www.cdc.gov/coronavirus/2019-nCoV/guidelines-clinicalspecimens.html>

<https://www.who.int/health-topics/coronavirus/laboratorydiagnostics-for-novel-coronavirus>

## Technical Support Contact Information

Applied BioCode, Inc. is dedicated to providing the best customer support available. If you have any questions or concerns, please contact Technical Services at:

1-833-BMB-TECH (1-833-262-8324)

Or email: [techsupport@apbiocode.com](mailto:techsupport@apbiocode.com)

### **USA Mailing Address:**

12130 Mora Dr., Unit 2, Santa Fe Springs, CA 90670, USA

Tel: +1-833-246-2633, Fax: +1-562-777-9805